GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors
1. GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. ...
Tag: copd
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis Late last week, the U.S. Food and Drug Administration approved Insmed’s Brinsupri ...
Mepolizumab decreases exacerbations in patients with eosinophilic COPD
1. In this randomized controlled trial, mepolizumab decreased the annualized rate of moderate or severe exacerbations when added to triple ...
Poor baseline lung function associated with increased risk of incident tuberculosis
1. The risk of tuberculosis (TB) was higher in individuals with obstructive or restrictive lung function impairment compared to those ...
Motivational interviewing not effective in reducing rehospitalisation and improving patient activation among patients with respiratory failure
1. Standalone motivational interviewing post-discharge did not reduce rehospitalization in older multimorbid patients with heart failure or chronic obstructive pulmonary ...
Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease
1. In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was not associated with improved clinical ...
#VisualAbstract: Tezepelumab Does Not Reduce Exacerbations in Adults with Chronic Obstructive Pulmonary Disease
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Point of care C-reactive protein testing may be useful in guiding antibiotic prescribing
1. C-reactive protein (CRP)-point-of-care tests can be used to guide antibiotic prescribing in primary care for patients with acute exacerbations ...
#VisualAbstract: High-Intensity Noninvasive Positive Pressure Ventilation Reduces Need for Endotracheal Intubation in COPD
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Dupilumab reduces exacerbations in COPD with type 2 inflammation
1. In this randomized controlled trial, patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received dupilumab ...
